Temozolomide-associated organizing pneumonitis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17550757.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.
Medical subject headings
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Pneumonia, Pneumocystis